Steven Cohen’s Definium Therapeutics DFTX Stock Holding History

Steven Cohen’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.8M	Buy	483,980 +308,490	+176%	+$7.62M	0.03%	810
2026 Q1	$3.32M	Sell	175,490 -4,951	-3%	-$84K	﹤0.01%	1972
2025 Q4	$2.42M	Sell	180,441 -43,859	-20%	-$543K	﹤0.01%	2358
2025 Q3	$2.64M	Buy	+224,300	New	+$2.09M	﹤0.01%	1333

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Steven Cohen's DFTX Position: Q2 2026 in Review

Steven Cohen increased its Definium Therapeutics (DFTX) stake by 176% in Q2 2026, buying an estimated $7.62M and bringing the position to 483,980 shares worth $22.8M. The position accounts for 0.03% of the portfolio, ranked #810.

Steven Cohen first reported a position in DFTX in Q3 2025 and has held it in 4 quarters since. 360 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Steven Cohen held 483,980 shares of Definium Therapeutics worth $22.8M as of Q2 2026.
Steven Cohen bought 308,490 Definium Therapeutics shares in Q2 2026, an estimated $7.62M.
Definium Therapeutics made up 0.03% of Steven Cohen's portfolio in Q2 2026, its #810 holding.
Steven Cohen first reported a position in Definium Therapeutics in Q3 2025 and has held it in 4 quarters since.
360 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.